BRAF V600 MUTATION
Clinical trials for BRAF V600 MUTATION explained in plain language.
Never miss a new study
Get alerted when new BRAF V600 MUTATION trials appear
Sign up with your email to follow new studies for BRAF V600 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can we safely reduce brain tumor meds? new study aims to find out
Disease control Recruiting nowThis study looks at whether people with a certain type of slow-growing brain tumor (low-grade glioma with a BRAF V600 mutation) can safely stop or lower their dose of two targeted drugs (dabrafenib and trametinib) after taking them for 12-24 months. About 96 participants will eit…
Matched conditions: BRAF V600 MUTATION
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis study tests an experimental oral drug, S241656, in people with advanced cancers (like lung, colon, or pancreatic) that have certain gene changes (KRAS, BRAF, or related). The drug is taken daily in 28-day cycles, either alone or with other cancer treatments. The goal is to f…
Matched conditions: BRAF V600 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New study aims to stop melanoma relapse after surgery
Disease control Recruiting nowThis study looks at whether giving additional treatment after surgery can reduce the chance of melanoma returning in people with advanced stage III or IV melanoma that has a BRAF V600 mutation. About 50 participants will receive a combination of drugs (encorafenib and binimetinib…
Matched conditions: BRAF V600 MUTATION
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC